Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Arena Pharmaceuticals Inc (ARNA) Com Stk US0.0001

Sell:$74.48 Buy:$74.51 Change: $1.11 (1.47%)
NASDAQ:0.20%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$74.48
Buy:$74.51
Change: $1.11 (1.47%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$74.48
Buy:$74.51
Change: $1.11 (1.47%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Contact details

Address:
6154 Nancy Ridge Dr
SAN DIEGO
92121-3223
United States
Telephone:
+1 (858) 4537200
Website:
www.arenapharm.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ARNA
ISIN:
US0400476075
Market cap:
$4.36 billion
Shares in issue:
57.65 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Tina Nova
    Independent Chairman of the Board
  • Amit Munshi
    Director, President and Chief Executive Officer
  • Laurie Stelzer
    Chief Financial Officer, Executive Vice President
  • Joan Schmidt
    Executive Vice President, General Counsel, Secretary
  • Vincent Aurentz
    Executive Vice President and Chief Business Officer
  • Robert Lisicki
    Executive Vice President and Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.